BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11517933)

  • 1. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
    Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
    Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.
    Zavasnik-Bergant V; Schweiger A; Bevec T; Golouh R; Turk V; Kos J
    Immunology; 2004 Jul; 112(3):378-85. PubMed ID: 15196205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
    Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
    J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p41 isoform of invariant chain is a chaperone for cathepsin L.
    Lennon-Duménil AM; Roberts RA; Valentijn K; Driessen C; Overkleeft HS; Erickson A; Peters PJ; Bikoff E; Ploegh HL; Wolf Bryant P
    EMBO J; 2001 Aug; 20(15):4055-64. PubMed ID: 11483509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
    Fineschi B; Sakaguchi K; Appella E; Miller J
    J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
    Mihelic M; Dobersek A; Guncar G; Turk D
    J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
    Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
    J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
    Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
    EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous Thyropin from p41 Invariant Chain Diminishes Cysteine Protease Activity and Affects IL-12 Secretion during Maturation of Human Dendritic Cells.
    Zavašnik-Bergant T; Bergant Marušič M
    PLoS One; 2016; 11(3):e0150815. PubMed ID: 26960148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
    Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
    J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant chain controls the activity of extracellular cathepsin L.
    Fiebiger E; Maehr R; Villadangos J; Weber E; Erickson A; Bikoff E; Ploegh HL; Lennon-Duménil AM
    J Exp Med; 2002 Nov; 196(9):1263-9. PubMed ID: 12417635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal cysteine proteases and antigen presentation.
    Rudensky A; Beers C
    Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
    Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
    J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteases, processing, and thymic selection.
    Cresswell P
    Science; 1998 Apr; 280(5362):394-5. PubMed ID: 9575085
    [No Abstract]   [Full Text] [Related]  

  • 15. Cathepsin S, but not cathepsin L, participates in the MHC class II-associated invariant chain processing in large yellow croaker (Larimichthys crocea).
    Li Q; Ao J; Mu Y; Yang Z; Li T; Zhang X; Chen X
    Fish Shellfish Immunol; 2015 Dec; 47(2):743-50. PubMed ID: 26475363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
    Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
    Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
    Honey K; Nakagawa T; Peters C; Rudensky A
    J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.
    Bania J; Gatti E; Lelouard H; David A; Cappello F; Weber E; Camosseto V; Pierre P
    Proc Natl Acad Sci U S A; 2003 May; 100(11):6664-9. PubMed ID: 12748383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus.
    Nakagawa T; Roth W; Wong P; Nelson A; Farr A; Deussing J; Villadangos JA; Ploegh H; Peters C; Rudensky AY
    Science; 1998 Apr; 280(5362):450-3. PubMed ID: 9545226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
    Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
    J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.